Tanomastat

Research use only, not for human use.

Tanomastat (BAY 129566) is a potent,orally available, non-peptidic inhibitor of MMP-2, MMP-3 and MMP-9 with 11, 143 and 301 nM, respectively.

Tanomastat (BAY 129566) is a potent,orally available, non-peptidic inhibitor of MMP-2, MMP-3 and MMP-9 with 11, 143 and 301 nM, respectively; inhibits extracellular matrix degradation and potentially inhibiting angiogenesis, tumor growth and invasion, and metastasis both in vitro and in vivo.Ovarian Cancer Phase 3 Discontinued.

Tanomastat (BAY 12-9566) (1-10000 nM; 6 hours) prevents matrix invasion by endothelial cells in a concentration-dependent manner (IC50=840 nM), without affecting cell proliferation.Tanomastat (BAY 12-9566) (1-00 μM; 5 days) inhibits tubule formation completely at 15-100 μM.

Tanomastat (BAY 12-9566) (100 mg/kg; p.o.; daily for a 7-week period) inhibits local tumor regrowth without causing any toxic effect, and inhibits the number and volume of lung metastases. Animal Model:Six- to eight-week-old female BALB/c nude mice (bearing MDA-MB-435 cells) Dosage:100 mg/kg Administration:p.o.; daily for a 7-week period Result:Inhibited local tumor regrowth by 58% without causing any toxic effect, and inhibited the number and volume of lung metastases by 57 and 88%, respectively.

BAY129566 | BAY 12-9566

Metabolic Enzyme/Protease

MMP

MMP

Cancer

Ovarian Cancer

179545-77-8

410.912

C23H19ClO3S

>98% (HPLC)

——

O=C(O)[C@@H](CSC1=CC=CC=C1)CC(C2=CC=C(C3=CC=C(Cl)C=C3)C=C2)=O

(S)-4-(4'-chloro-[1,1'-biphenyl]-4-yl)-4-oxo-2-((phenylthio)methyl)butanoic acid

(-20℃)

With Ice Pack

≥ 2 years